Elan: 2005

Elan Drug Technologies

Research &
Development

Investor Relations

Elan News: 2005

22nd December 2005

Elan to Present at Healthcare Conferences in January 2006

17th November 2005

Biogen Idec and Elan Announce FDA Acceptance of Supplemental Biologics License Application and Priority Review Designation for TYSABRI® in Multiple Sclerosis

9th November 2005

The National MS Society, Biogen Idec, Elan, and MSWorld Recognize MS Leaders of Hope(SM) Award Winners

27th October 2005

Elan Reports Third Quarter 2005 Financial Results

17th October 2005

Elan and Biogen Idec Announce TYSABRI® Safety Evaluation Findings in Crohn's Disease and Rheumatoid Arthritis Patients; TYSABRI Safety Evaluation Complete; No New Confirmed Cases of PML

4th October 2005

Elan Announces Webcast of Third Quarter 2005 Financial Results

29th September 2005

Elan to File Interim Six Month IFRS Financials with the Irish and London Stock Exchanges

27th September 2005

Elan Announces Commencement of Exchange Offer for US$1.15 Billion Aggregate Principal Amount of Notes

26th September 2005

Biogen Idec and Elan Submit Supplemental Biologics License Application to the FDA for TYSABRI® in Multiple Sclerosis

20th September 2005

Elan and Biogen Idec Provide an Update on TYSABRI®

9th August 2005

Biogen Idec and Elan Announce TYSABRI® Safety Evaluation Update

28th July 2005

Elan Reports Second Quarter 2005 Financial Results

26th July 2005

Institute for the Study of Aging Receives Generous Donation from Elan Pharmaceuticals to Create a New Alzheimer's Disease Research Program

18th July 2005

Two-Year SENTINEL Data Evaluating TYSABRI® in Addition to AVONEX® Reinforce Efficacy in Multiple Sclerosis

14th July 2005

Elan Announces Webcast of Second Quarter 2005 Financial Results

30th June 2005

TYSABRI® Phase III Induction Trial in Crohn's Disease Meets Primary Endpoint; TYSABRI Induced Statistically Significant Response and Remission in Patients with Active Disease

14th June 2005

Elan Settles Legal Action with Former CEO

8th June 2005

Elan Completes Retirement of over $240 Million of 2008 Debt

1st June 2005

Elan Retires over $240 Million of 2008 Debt

31st May 2005

Elan Announces the Appointment of New Board Directors

26th May 2005

Elan Holds Its AGM, All Resolutions Passed

17th May 2005

Elan Announces Webcast of Annual General Meeting on May 26, 2005

16th May 2005

Second Annual MS Leaders of Hope Awards to Recognize Resolve and Innovation in People Living With MS

28th April 2005

Elan Reports First Quarter 2005 Financial Results

13th April 2005

Positive One-Year Data From SENTINEL Trial Evaluating Addition of TYSABRI® to AVONEX® Presented at American Academy of Neurology Meeting

12th April 2005

TYSABRI® Two-Year Monotherapy Data Support Positive One-Year Efficacy Findings and Show Significant Reduction in Risk of Disability Progression

11th April 2005

Elan Sets Date of April 28 for First Quarter 2005 Financial Results, and May 26 for the Annual General Meeting; Elan Announces Filing of 2004 Form 20-F with SEC

30th March 2005

Elan and Biogen Idec Announce TYSABRI® Update

11th March 2005

Elan to Present at SG Cowen 25th Annual Healthcare Conference

3rd March 2005

Biogen Idec and Elan Announce Update on TYSABRI®

28th February 2005

Elan Announces Webcast of Voluntary Suspension of TYSABRI®

28th February 2005

Biogen Idec and Elan Announce Voluntary Suspension of TYSABRI®

22nd February 2005

Elan Receives Approval From The European Commission To Market PRIALT™ (100 Micrograms/Ml Solution For Infusion) For Severe Chronic Pain

17th February 2005

TYSABRI® Two-Year Monotherapy Trial Demonstrates Significant Impact on Disability Progression and Relapse Rate in Multiple Sclerosis

8th February 2005

Elan Announces Final Settlement of SEC Investigation; Settlement concludes all aspects of the investigation

8th February 2005

Elan Reports Fourth Quarter and Full-Year 2004 Financial Results

3rd February 2005

Japanese Patent Office Issues Patent Certificate to Elan for Its NanoCrystal-TM- Technology

18th January 2005

Elan to Present at the Piper Jaffray Healthcare Conference

12th January 2005

Elan's Proprietary NanoCrystal® Technology is Used by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&J PRD) in Phase III Clinical Trial of Paliperidone Palmitate

10th January 2005

Elan Announces Webcast of Fourth Quarter and Full Year 2004 Financial Results

7th January 2005

Elan and Roche Expand Nanocrystal Technology License

7th January 2005

Kyran McLaughlin Assumes Chairmanship of Elan Board Of Directors

5th January 2005

Elan to Present at the JP Morgan 23rd Annual Healthcare Conference

4th January 2005

Elan to Present at the Morgan Stanley Pharmaceutical CEO's Unplugged Conference

Copyright © 2001- 2004 Elan Corporation, plc, Dublin, Ireland. All rights reserved. | Privacy Policy | Terms of use